Categories Analysis, Health Care

Strong performance of oncology products bode well for AbbVie (ABBV) going forward

The company expects GAAP EPS to be $4.12-4.22 and adjusted EPS to be $10.35-10.45 for FY2020

AbbVie Inc. (NYSE: ABBV) reported better-than-expected results for the second quarter of 2020 on Friday. The company reported a 26% increase in total revenue to $10.4 billion and a 4% increase in adjusted EPS to $2.34.

Although segment performance remained mixed, oncology delivered strong results for the quarter, growing 26% year-over-year, driven by double-digit increases in Imbruvica and Venclexta. Imbruvica revenues grew 17.2% while Venclexta climbed 79.2%.


AbbVie’s oncology business aims to treat complex forms of cancer through its Imbruvica and Venclexta products. Imbruvica is currently used in the treatment of chronic lymphocytic leukemia, mantle cell lymphoma and marginal zone lymphoma, among others. Venclexta is used to treat chronic lymphocytic leukemia, small lymphocytic leukemia and acute myeloid leukemia.  


Sales of Imbruvica and Venclexta have consistently improved over the past three years. Imbruvica registered a year-over-year growth of nearly 40% in 2018 and 30% in 2019 while Venclexta saw its sales increase more than 500% over the past three years. In fiscal year 2019, Imbruvica revenues amounted to $4.6 billion while Venclexta revenues totaled $792 million.

Imbruvica revenues benefited from the continued penetration of the product for the treatment of chronic lymphocytic leukemia as well as favorable pricing. Venclexta gained from market share gains due to additional regulatory approvals.

AbbVie (ABBV) Q2 2020 Earnings Infograph

In the first quarter of 2020, total sales of oncology increased 32% with a nearly 21% increase in Imbruvica and an over 100% increase in Venclexta. In the second quarter, Imbruvica gained due to strong performance in chronic lymphocytic leukemia where the company is the market leader. Venclexta saw strong growth in chronic lymphocytic leukemia and acute myeloid leukemia.


AbbVie has several data readouts and study starts happening this year. The company reported positive results from the Phase III VIALE-A study for the treatment of Venclexta plus azacitidine in patients with acute myeloid lymphoma. The company also initiated two Phase III studies to evaluate Venclexta as a maintenance therapy in acute myeloid lymphoma.

AbbVie announced an oncology collaboration with Genmab to develop and commercialize three next-generation bispecific antibody products and establish a discovery collaboration to create additional differentiated antibody-based therapeutics for cancer.


Following its acquisition of Allergan, AbbVie issued combined company guidance for full year 2020. The company expects GAAP EPS to be $4.12-4.22 and adjusted EPS to be $10.35-10.45.

Also read: AbbVie (ABBV) Q2 2020 results beat estimates; updates FY20 outlook

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

Infographic: Key highlights from Best Buy (BBY) Q1 2023 earnings results

Best Buy Co., Inc. (NYSE: BBY) reported first quarter 2023 earnings results today. Enterprise revenue dropped to $10.6 billion from $11.6 billion in the year-ago period. Comparable sales were down

AutoZone (AZO) Q3 Earnings: Key financials and quarterly highlights

AutoZone, Inc. (NYSE: AZO) reported third quarter 2022 earnings results today. Net sales increased 5.9% year-over-year to $3.9 billion. Domestic same-store sales increased 2.6%. Net income decreased 0.6% to $592.6 million, while

Infographic: Zoom Video Communications (ZM) Q1 2023 earnings results

Zoom Video Communications (NASDAQ: ZM)  reported lower earnings and higher revenues for the first quarter of 2023. Earnings topped Wall Street's expectations, while revenues matched the estimates. Adjusted earnings, excluding

Add Comment
Viewing Highlight